Ho, Shin-Shin http://orcid.org/0000-0001-9974-8614
Tsai, Tsen-Fang http://orcid.org/0000-0002-1498-1474
Article History
Accepted: 6 June 2022
First Online: 5 July 2022
Declarations
:
: No sources of funding were received to assist in the preparation of this article.
: Shin-Shin Ho has no conflicts of interest that are directly relevant to the contents of this article. Tsen-Fang Tsai has conducted clinical trials or received honoraria for serving as a consultant for Abbvie, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eli Lilly, Galderma, Janssen-Cilag, Merck Sharp & Dohme, Novartis International AG, Pfzer Inc., and UCB Pharma.
: This study has been approved by the local Institutional Review Board (20190412RINC, 200712123R).
: All patients provided written informed consent.
: The data that support the findings of this study are available from the corresponding author upon reasonable request.
: Not applicable.
: All authors contributed to the study conception and design. The literature search and data analysis were performed by Shin-Shin Ho and Tsen-Fang Tsai. The first draft of the manuscript was written by Shin-Shin Ho and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.